Maravai LifeSciences Holdings (MRVI) Financials: History & Chart

Maravai LifeSciences Holdings, Inc.(MRVI)

Biotechnology · San Diego, CA

$7.85-0.67 (-7.86%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Maravai LifeSciences Holdings, Inc.

Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology. Meanwhile, the Biologics Safety Testing segment offers analytical products vital for developing biologic manufacturing processes. Its offerings include bespoke antibody and assay development services tailored to specific products, alongside HCP ELISA kits, various other ELISA kits for identifying bioprocess impurities and contaminants, ancillary reagents, and custom service solutions. Maravai's clientele spans biopharmaceutical companies, other life sciences and biopharmaceutical research firms, academic research institutions, and in vitro diagnostics companies. Incorporated in 2020, Maravai LifeSciences Holdings, Inc. maintains its headquarters in San Diego, California.

San Diego, CA

415 employees

www.maravai.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Bernd Brust

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	208.78M	51.44M	65.84M	49.87M	41.63M	47.40M	46.85M	56.41M	65.20M
Cost of Goods Sold	136.53M	30.79M	32.14M	37.62M	35.98M	39.63M	39.13M	37.44M	36.83M
Gross Profit	72.25M	20.65M	33.70M	12.24M	5.66M	7.77M	7.72M	18.96M	28.37M
Gross Profit Margin	34.6%	40.1%	51.2%	24.5%	13.6%	16.4%	16.5%	33.6%	43.5%
Total Operating Expenses	-23.84M	35.74M	31.23M	18.98M	-109.78M	74.05M	56.89M	57.09M	197.49M
Research & Development	21.15M	3.70M	3.89M	3.79M	9.77M	4.88M	4.89M	4.56M	4.34M
Selling, General & Administrative	152.74M	32.07M	27.34M	15.19M	78.14M	38.58M	39.56M	41.24M	39.09M
Operating Income (EBIT)	96.09M	-15.09M	2.47M	-6.74M	115.44M	-66.28M	-49.16M	-38.13M	-169.11M
Operating Margin	46.0%	-29.3%	3.8%	-13.5%	277.3%	-139.8%	-104.9%	-67.6%	-259.4%
Income Before Tax (EBT)	-136.49M	-21.80M	-6.53M	-63.01M	-45.15M	-74.13M	-52.69M	-46.50M	-175.64M
Interest Income	20.72M	1.16M	1.87M	2.38M	15.31M	3.03M	3.23M	6.04M	7.07M
Interest Expense	23.96M	4.81M	5.75M	6.55M	6.84M	6.82M	6.78M	11.26M	13.63M
Other Income/Expense	-232.57M	-6.71M	-9.00M	-56.27M	-160.59M	-7.85M	-3.53M	-8.37M	-6.53M
Net Income	-77.39M	-12.42M	-3.73M	-35.68M	-25.56M	-39.59M	-29.95M	-26.14M	-99.04M
Income Tax Expense	-408K	-171K	-151K	6K	-92K	-4.29M	162K	-7K	311K
Net Profit Margin	-37.1%	-24.1%	-5.7%	-71.6%	-61.4%	-83.5%	-63.9%	-46.4%	-151.9%
EBITDA	151.42M	-3.31M	15.45M	8.00M	131.28M	-50.89M	-34.25M	-23.60M	-155.07M
EBITDA Margin	72.5%	-6.4%	23.5%	16.0%	315.4%	-107.4%	-73.1%	-41.8%	-237.8%
Depreciation & Amortization	55.34M	11.78M	12.98M	14.73M	15.84M	15.39M	14.91M	14.53M	14.04M
EPS Basic	-0.54	-0.08	-0.03	-0.25	-0.18	-0.27	-0.21	-0.18	-0.70
EPS Diluted	-0.54	-0.08	-0.03	-0.25	-0.18	-0.27	-0.21	-0.18	-0.70
Weighted Average Basic Shares	148.00M	148.00M	146.43M	145.07M	144.68M	144.24M	143.43M	139.73M	141.56M
Weighted Average Diluted Shares	148.00M	148.00M	146.43M	145.07M	144.68M	144.24M	143.43M	139.73M	141.56M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	185.74M	259.19M	288.94M	883.00M	799.24M	284.10M	143.14M	123.83M
Cost of Goods Sold	152.35M	150.88M	148.74M	168.96M	140.56M	79.65M	66.85M	60.77M
Gross Profit	33.39M	108.31M	140.20M	714.04M	658.68M	204.45M	76.29M	63.07M
Gross Profit Margin	18.0%	41.8%	48.5%	80.9%	82.4%	72.0%	53.3%	50.9%
Total Operating Expenses	40.13M	343.93M	171.85M	139.83M	104.03M	84.55M	52.30M	45.69M
Research & Development	23.33M	19.22M	17.28M	18.37M	15.22M	9.30M	3.63M	4.50M
Selling, General & Administrative	171.47M	161.77M	151.39M	129.26M	100.06M	94.25M	48.35M	41.19M
Operating Income (EBIT)	-6.74M	-235.62M	-31.65M	574.22M	554.64M	119.90M	23.99M	16.44M
Operating Margin	-3.6%	-90.9%	-11.0%	65.0%	69.4%	42.2%	16.8%	13.3%
Income Before Tax (EBT)	-234.97M	-261.48M	617.74M	551.47M	530.76M	81.70M	-5.85M	-16.50M
Interest Income	23.95M	27.40M	27.73M	2.34M	N/A	N/A	N/A	N/A
Interest Expense	26.99M	47.70M	45.89M	20.41M	30.26M	30.74M	29.96M	27.40M
Other Income/Expense	-228.24M	-25.86M	649.38M	-22.74M	-23.88M	-38.21M	-29.84M	-32.93M
Net Income	-130.77M	-144.85M	-119.03M	220.21M	182.04M	76.89M	-8.49M	-17.73M
Income Tax Expense	-4.21M	-1.86M	756.11M	60.81M	61.52M	2.88M	-652K	417K
Net Profit Margin	-70.4%	-55.9%	-41.2%	24.9%	22.8%	27.1%	-5.9%	-14.3%
EBITDA	54.13M	-178.75M	17.13M	612.32M	579.40M	145.74M	48.07M	38.78M
EBITDA Margin	29.1%	-69.0%	5.9%	69.3%	72.5%	51.3%	33.6%	31.3%
Depreciation & Amortization	60.87M	56.87M	48.78M	38.10M	24.75M	25.84M	24.08M	22.35M
EPS Basic	-0.91	-1.05	-0.90	1.67	1.59	N/A	-0.05	-0.20
EPS Diluted	-0.91	-1.05	-0.90	1.67	1.56	N/A	-0.05	-0.20
Weighted Average Basic Shares	145.07M	137.91M	131.92M	131.54M	114.79M	96.65M	96.65M	88.97M
Weighted Average Diluted Shares	145.07M	137.91M	131.92M	131.69M	121.97M	96.65M	96.65M	88.97M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.